Evidence of a role for phosphatidylinositol synthesis in human amnion cell proliferation.
Phosphatidylinositol (PtdIns) is the key precursor of phosphoinositide-derived intracellular mediators. The effects of changing the rate of PtdIns synthesis on mitogenic activity of human amnion-derived WISH cells were investigated. Incubation of the cells with [3H]inositol caused a time- and dose-dependent PtdIns labeling. Exogenous Ca2+ inhibited [3H]inositol incorporation in a dose-dependent fashion; half-maximal inhibition occurred with 0.3-1.0 mM Ca2+. In contrast, removal of cytosolic Ca2+ by ionophore A23187 and 1 mM EGTA induced enhancement of the PtdIns labeling as a function of A23187 concentration, perhaps through release of inhibitory effects of endogenous Ca2+. The A23187-stimulated PtdIns labeling with [3H]inositol was not abolished by additional unlabeled inositol, suggesting that [3H]inositol labeling of PtdIns occurred mainly through de novo synthesis catalyzed by PtdIns synthase (EC 2.7.8.11). In cells with PtdIns synthase activity decreased by exogenous Ca2+, [3H]thymidine incorporation was also inhibited, while A23187 caused dose-dependent enhancement of thymidine incorporation. The changes in PtdIns synthase activity occurred in parallel with changes in mitogenic activity caused by increasing the dose of exogenous Ca2+ or A23187. A similar lowering of mitogenic activity was observed upon suppression of PtdIns synthase by pemirolast potassium (9-methyl-3-1H-tetrazol-5yl-4H-pyrido[1,2-a]pyridin-4-one potassium) via a Ca(2+)-independent mechanism. These data demonstrate that changes in PtdIns synthase activity by some agents acting via different mechanisms are associated with parallel changes in thymidine incorporation, and suggest that PtdIns production is tightly coupled to cell proliferation in human amnion cells.
Ohno
T
T
Department of Obstetrics and Gynecology, Gifu University School of Medicine, Japan.
Imai
A
A
Furui
T
T
Matsunami
K
K
Matsuda
T
T
Tamaya
T
T
D000650:Amnion / Q000166:cytology* / Q000378:metabolism; D051607:CDP-Diacylglycerol-Inositol 3-Phosphatidyltransferase; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D004247:DNA / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004533:Egtazic Acid / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006633:Histamine Antagonists / Q000494:pharmacology; D006801:Humans; D007294:Inositol / Q000378:metabolism; D008274:Magnesium / Q000494:pharmacology; D008565:Membrane Proteins; D010716:Phosphatidylinositols / Q000096:biosynthesis*; D010770:Phosphotransferases / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology; D011744:Pyrimidinones / Q000494:pharmacology; D013997:Time Factors; D017855:Transferases (Other Substituted Phosphate Groups)
D006633:Histamine Antagonists; D008565:Membrane Proteins; D010716:Phosphatidylinositols; D011725:Pyridines; D011744:Pyrimidinones; C055139:pemirolast; D000001:Calcimycin; D007294:Inositol; D004533:Egtazic Acid; D004247:DNA; D010770:Phosphotransferases; D017855:Transferases (Other Substituted Phosphate Groups); C496766:CDIPT protein, human; D051607:CDP-Diacylglycerol-Inositol 3-Phosphatidyltransferase; D008274:Magnesium; D002118:Calcium